Avtor/Urednik		Vrtovec, B; Thomas, CD; Radovančević, R; Frasier, OH; Radovančević, B
Naslov		Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients
Tip		članek
Vir		J Heart Lung Transplant
Vol. in št.		Letnik 23, št. 4
Leto izdaje		2004
Obseg		str. 461-5
Jezik		eng
Abstrakt		We compared the use of intravenous ganciclovir and cytomegalovirus hyperimmune globulin (CMVIG) as a pre-emptive treatment for cytomegalovirus (CMV)-positive heart transplant recipients. Of 59 CMV-seropositive adult heart transplant recipients enrolled in Group 1,37 tested positive for pp65 antigen within 12 weeks post-transplantation. These patients were randomized to receive either intravenous ganciclovir (n = 23) or CMVIG (n = 14). Group 2 included 133 CMV-seropositive heart transplant recipients who were not tested for CMV antigenemia and who received no anti-CMV therapy. CMV disease developed in 0 of 59 patients from Group 1, and in 27 of 133 patients (20%) in Group 2 (p = 0.0001). The incidence of superinfections was lower in Group 1 (0.28 ± 0.46) than in Group 2 (1.10 1- 1.33) (p = 0.01). The 2 groups did not differ with regard to incidence of rejection (0.7 ± 0.9 in Group 1 vs 1.0 ± 1.2 in Group 2; p = NS), transplant coronary artery disease at 1 year (14% in Group 1 vs 16°/ in Group 2; p = NS) or post-transplant lymphoproliferative disease (0% in Group 1 vs 2% in Group 2; p = NS). Ganciclovir and CMVIG therapies were associated with similar rates of rejection (0.52 ± 0.6 with ganciclovir vs 0.50 ± 0.60 with CMVIG; p = NS), superinfection (0.30 ± 0.48 with ganciclovir vs 0.25 ± 0.46 with CMVIG; p = NS), and transplant coronary artery disease at 1 year <13% with ganciclovir vs 14% with CMVIG, p = NS). The pre-emptive anti-CMV approach is superior to prophylaxis in CMV-seropositive heart transplant recipients. Both ganciclovir and CMVIG are equally effective. J Heart Lung Transplant 2004;23:461-465.
Deskriptorji		HEART TRANSPLANTATION CYTOMEGALOVIRUS INFECTIONS ANTIVIRAL AGENTS GANCICLOVIR IMMUNOGLOBULINS AGE FACTORS SEX FACTORS DRUG COSTS FOLLOW-UP STUDIES IMMUNIZATION, PASSIVE PHOSPHOPROTEINS TREATMENT OUTCOME VIRAL MATRIX PROTEINS